KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to -$7.4 billion.

  • Gilead Sciences' Enterprise Value fell 4514.74% to -$7.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.4 billion, marking a year-over-year decrease of 4514.74%. This contributed to the annual value of -$10.1 billion for FY2024, which is 3711.21% down from last year.
  • Latest data reveals that Gilead Sciences reported Enterprise Value of -$7.4 billion as of Q3 2025, which was down 4514.74% from -$5.3 billion recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' Enterprise Value registered a high of -$2.9 billion during Q2 2024, and its lowest value of -$10.1 billion during Q4 2024.
  • Moreover, its 5-year median value for Enterprise Value was -$5.9 billion (2023), whereas its average is -$6.2 billion.
  • As far as peak fluctuations go, Gilead Sciences' Enterprise Value skyrocketed by 7604.49% in 2021, and later crashed by 8546.92% in 2025.
  • Quarter analysis of 5 years shows Gilead Sciences' Enterprise Value stood at -$6.5 billion in 2021, then grew by 1.67% to -$6.4 billion in 2022, then dropped by 14.53% to -$7.3 billion in 2023, then tumbled by 37.11% to -$10.1 billion in 2024, then rose by 26.22% to -$7.4 billion in 2025.
  • Its Enterprise Value stands at -$7.4 billion for Q3 2025, versus -$5.3 billion for Q2 2025 and -$8.0 billion for Q1 2025.